Roflumilast, a Phosphodiesterase 4 Inhibitor, Alleviates Bleomycin-induced Lung Injury

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Jan 22

PMID 19154443

Citations 45

Authors

J Cortijo

A Iranzo

X Milara

M Mata

M Cerda-Nicolas

A Ruiz-Sauri

H Tenor

A Hatzelmann

E J Morcillo

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The effects of a phosphodiesterase 4 (PDE4) inhibitor, roflumilast, on bleomycin-induced lung injury were explored in 'preventive' and 'therapeutic' protocols and compared with glucocorticoids.

Experimental Approach: Roflumilast (1 and 5 mg.kg(-1).d(-1), p.o.) or dexamethasone (2.5 mg.kg(-1).d(-1), p.o.) was given to C57Bl/6J mice from day 1 to 14 (preventive) or day 7 to 21 (therapeutic) after intratracheal bleomycin (3.75 U.kg(-1)). In Wistar rats, roflumilast (1 mg.kg(-1).d(-1), p.o.) was compared with methylprednisolone (10 mg.kg(-1).d(-1), p.o.) from day 1 to 21 (preventive) or from day 10 to 21 (therapeutic), following intratracheal instillation of bleomycin (7.5 U.kg(-1)). Analyses were performed at the end of the treatment periods.

Key Results: Preventive. Roflumilast reduced bleomycin-induced lung hydroxyproline, lung fibrosis and right ventricular hypertrophy; muscularization of intraacinar pulmonary vessels was also attenuated. The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts. Therapeutic. In mice, roflumilast but not dexamethasone reduced bleomycin-induced lung alphaI(I)collagen transcripts, fibrosis and right ventricular hypertrophy. Similar results were found in the rat.

Conclusions And Implications: Roflumilast prevented the development of bleomycin-induced lung injury, and alleviated the lung fibrotic and vascular remodeling response to bleomycin in a therapeutic protocol, the latter being resistant to glucocorticoids.

Citing Articles

Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats.

Maded Z, Lassoued M, Taqa G, Fawzi H, Abdulqader A, Jabir M Int J Nanomedicine. 2024; 19:13113-13134.

PMID: 39679247 PMC: 11638079. DOI: 10.2147/IJN.S492180.

Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations.

Milara J, Ribera P, Marin S, Montero P, Roger I, Cortijo J Mol Med. 2024; 30(1):134.

PMID: 39223490 PMC: 11370283. DOI: 10.1186/s10020-024-00906-8.

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives.

Vancheri C, Sciacca E, Muscato G, Spicuzza L, Fruciano M, Gili E Multidiscip Respir Med. 2024; 19.

PMID: 38869027 PMC: 11186439. DOI: 10.5826/mrm.2024.982.

The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice.

Kim K, Kim Y, Joo H, Kim J In Vivo. 2024; 38(3):1127-1132.

PMID: 38688656 PMC: 11059869. DOI: 10.21873/invivo.13547.

The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation.

Almalki R Drug Des Devel Ther. 2024; 18:453-462.

PMID: 38374827 PMC: 10875972. DOI: 10.2147/DDDT.S438703.

References

Hatzelmann A, Schudt C . Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001; 297(1):267-79. View

Martorana P, Beume R, Lucattelli M, Wollin L, Lungarella G . Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005; 172(7):848-53. DOI: 10.1164/rccm.200411-1549OC. View

Fichtner-Feigl S, Strober W, Kawakami K, Puri R, Kitani A . IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2005; 12(1):99-106. DOI: 10.1038/nm1332. View

Belperio J, Dy M, Burdick M, Xue Y, Li K, Elias J . Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002; 27(4):419-27. DOI: 10.1165/rcmb.2002-0009OC. View

Hohlfeld J, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D . Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008; 21(4):616-23. DOI: 10.1016/j.pupt.2008.02.002. View

Ortiz L, Champion H, Lasky J, Gambelli F, Gozal E, Hoyle G . Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol. 2002; 282(6):L1209-21. DOI: 10.1152/ajplung.00144.2001. View

Wollin L, Bundschuh D, Wohlsen A, Marx D, Beume R . Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther. 2005; 19(5):343-52. DOI: 10.1016/j.pupt.2005.09.002. View

Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock I . Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology. 2004; 45(5):477-84. DOI: 10.1111/j.1365-2559.2004.01952.x. View

Lovgren A, Jania L, Hartney J, Parsons K, Audoly L, FitzGerald G . COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2006; 291(2):L144-56. DOI: 10.1152/ajplung.00492.2005. View

10.

Serrano-Mollar A, Closa D, Cortijo J, Morcillo E, Prats N, Gironella M . P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax. 2002; 57(7):629-34. PMC: 1746384. DOI: 10.1136/thorax.57.7.629. View

11.

Keerthisingam C, Jenkins R, Harrison N, Booth H, Laurent G, Hart S . Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 2001; 158(4):1411-22. PMC: 1891895. DOI: 10.1016/s0002-9440(10)64092-8. View

12.

Sanz M, Cortijo J, Morcillo E . PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther. 2005; 106(3):269-97. DOI: 10.1016/j.pharmthera.2004.12.001. View

13.

Houslay M, Schafer P, Zhang K . Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005; 10(22):1503-19. DOI: 10.1016/S1359-6446(05)03622-6. View

14.

ONeill C, Giri S, Wang Q, Perricone M, Hyde D . Effects of dibutyrylcyclic adenosine monophosphate on bleomycin-induced lung toxicity in hamsters. J Appl Toxicol. 1992; 12(2):97-111. DOI: 10.1002/jat.2550120206. View

15.

Kohyama T, Liu X, Wen F, Zhu Y, Wang H, Kim H . PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol. 2002; 26(6):694-701. DOI: 10.1165/ajrcmb.26.6.4743. View

16.

Izbicki G, Segel M, Christensen T, Conner M, Breuer R . Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002; 83(3):111-9. PMC: 2517673. DOI: 10.1046/j.1365-2613.2002.00220.x. View

17.

Ashcroft T, Simpson J, Timbrell V . Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988; 41(4):467-70. PMC: 1141479. DOI: 10.1136/jcp.41.4.467. View

18.

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View

19.

Gensch E, Gallup M, Sucher A, Li D, Gebremichael A, Lemjabbar H . Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem. 2004; 279(37):39085-93. DOI: 10.1074/jbc.M406866200. View

20.

Bundschuh D, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R . In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001; 297(1):280-90. View